The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression.
Compound Placebo Psilocybin
Start date 01 January 2019
End date 27 September 2021
Chance of happening 100%
Phase Phase II
Age 18- 99
Trial DetailsThe Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study
NCT Number NCT03775200
Sponsors & CollaboratorsCOMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.
PapersPsilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing
This preprint article of a language model (NLP, BART) finds that the audio from psychological support sessions (in the COMP360 trial for treatment-resistant depression, n=90 at 12 weeks) can predict clinical outcomes with high (85%) accuracy. The implications of this research signal that audio recordings can be used to predict who will respond to treatment and possibly aid in helping identify who would need more support.
Measures UsedMontgomery-Asberg Depression Rating Scale
A ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.